Research library

B

grade

Pharmacotherapy, including liraglutide, can support weight management in children but should not replace comprehensive behavioral and family-based interventions.

1.71 kg/m² BMI reduction with medication plus behavioral treatment vs behavioral treatment alone, n=4331.

summary

B

grade

ACEI/ARB therapy was associated with a 28% lower risk of new-onset chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

HR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.

summary

B

grade

In patients with bipolar disorder and chronic kidney disease, SGLT2 inhibitors may show a non-significant trend toward lower kidney replacement therapy risk but are associated with higher healthcare utilization compared to GLP-1 receptor agonists.

aHR 0.87, 95% CI 0.71-1.06 for KRT risk in full cohort.

summary

C

grade

Validating antibodies is crucial for reliable detection of p16INK4A in pancreas research, as shown by the consistent performance of one monoclonal antibody.

Not reported in abstract.

summary

B

grade

Higher adherence to the Mediterranean diet may reduce the risk of diabetic nephropathy, but current evidence is insufficient to establish causality.

21% to 86% reduction in risk of DN with higher MD adherence.

summary

D

grade

Not reported in abstract.

summary

B

grade

GLP-1 receptor agonists are increasingly used in European sleep clinics, but there is considerable variability in how they are managed, indicating a need for better guidelines and coordination in care.

42% of centres reported that GLP-1RA therapy could be initiated by sleep physicians within the sleep clinic.

summary

D

grade

Liraglutide had an ADR reporting rate of 1,326.64 per million items, significantly lower than newer therapies like tirzepatide, which reported 27,511.52 per million items.

Liraglutide 1,326.64 (1,268.16–1,387.82) per million items.

summary

C

grade

MLF may help improve metabolic parameters in diabetes models, but further research is needed to confirm these effects in humans.

Fasting blood glucose reduced significantly, p<0.05.

summary

D

grade

Not reported in abstract.

summary

D

grade

This systematic review indicates that obesity management medications, including liraglutide, are associated with significant weight loss compared to placebo, but specific numeric outcomes for liraglutide were not detailed.

Not reported in abstract.

summary

B

grade

This study found that individual GLP-1 receptor agonists and SGLT2 inhibitors show broadly similar cardiovascular effectiveness in adults with type 2 diabetes, but the clinical significance of these findings may be limited.

meta-analytic HR 1.05 for 3-point MACE (95% CI 0.79-1.39)

summary

B

grade

Weight loss drug users in Norway show higher rates of comorbidities compared to the general population, highlighting the need for careful public health strategies.

4,603 liraglutide users identified during 2023-2024.

summary

B

grade

GLP-1 receptor agonists may be associated with a higher risk of allodynia compared to bupropion-naltrexone, with an adjusted hazard ratio of 2.15.

aHR 2.15 (95% CI 1.57–2.96)

summary

A

grade

Liraglutide treatment is associated with significant increases in certain lysophospholipids and decreases in triglycerides in individuals with type 2 diabetes, but the clinical implications of these changes require further investigation.

Not reported in abstract.

summary

D

grade

Falls are reported significantly more often in older adults using GLP-1 receptor agonists, with a reporting odds ratio of 2.75. This finding highlights the need for careful monitoring in this population.

ROR for falls was 2.75 (95% CI 2.47–3.06).

summary

A

grade

The study found no significant improvement in overall insulin sensitivity with Akkermansia muciniphila, but some subgroups showed potential benefits in insulin sensitivity and GLP-1 levels.

12% improvement in HOMA-based hepatic insulin sensitivity in prediabetic subgroup, p=0.05.

summary

C

grade

TruCBN™ showed no adverse effects in rats at doses up to 400 mg/kg/day, but its safety in humans remains unverified.

NOAEL for TruCBN™ of 400 mg/kg/day.

summary

A

grade

GLP-1 receptor agonists may lead to significant reductions in body weight and other cardiometabolic risk factors in overweight or obese Chinese adults, but further research is needed to confirm these findings.

MD: -10.06 kg; 95% CI: -15.56 to -4.56 for body weight reduction.

summary

C

grade

Exendin-4 functionalization appears to enhance the activity of lipid-based nanoemulsions, with 10 nM ex-4 NE showing effects similar to 1000 nM free ex-4, indicating potential for improved therapeutic delivery.

10 nM ex-4 NE produced effects comparable to 1000 nM free ex-4.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary